Medical disclaimer
This article is for general education and is not medical advice. It is not a substitute for evaluation, diagnosis, or treatment by a licensed clinician. Talk with a qualified clinician about your individual situation.
Compounded medications
Arbor is a technology platform. Medical evaluations are conducted by independent, licensed healthcare providers who decide whether treatment is appropriate. Compounded medications are prepared by licensed U.S. pharmacies for individual patients and are not reviewed by the FDA for safety or effectiveness.
Sources
- Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1). N Engl J Med. 2026.
- Bellido V, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2). Lancet. 2026;408:1455-1472.
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. N Engl J Med. 2023;389:514-526.
- ClinicalTrials.gov. TRANSCEND-T2D-2: Retatrutide compared with semaglutide in type 2 diabetes (NCT06260722).
- ClinicalTrials.gov. TRIUMPH-Outcomes: Retatrutide and cardiovascular and kidney outcomes (NCT06383390).
- DailyMed. Wegovy (semaglutide) injection and tablets, prescribing information (June 2026).
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
- Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025;393:26-36.
- U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026).
- U.S. Food and Drug Administration. Novel Drug Approvals for 2026.
- U.S. Securities and Exchange Commission. Form 8-K, Exhibit 99.1, second-quarter 2026 results of the manufacturer of retatrutide (August 5, 2026).








